As part of the company’s quality control department, the labs are responsible for testing the in-process and finished products, as well as raw materials and components, for the company’s cGMP sterile manufacturing operations. The labs are also responsible for environmental monitoring and analytical method development.
Dr. Stoker brings 20 years of professional experience managing pharmaceutical labs responsible for quality control. Most recently, he served as director of the quality control lab at Dendreon. Prior to that, he directed quality control and analytical laboratories for Nektar Therapeutics.
“While continuous quality compliance is key to OsoBio’s business success, it’s even more important to the patients who rely upon the medications we manufacture – and we try to never lose sight of that fact,” said Milton Boyer, president of OsoBio. “Paul will lead a team of scientists who are knowledgeable, capable and highly committed to integrity – delivering excellence to both our clients and the patients we collectively serve.”